EUVIMEDEUVIMED entdecken
Crossref

Selexipag Dosing Strategies for Pediatric Patients with Pulmonary Arterial Hypertension

Madeline Grossman, Stephen Walker, E Zachary Ramsey

Pediatric Cardiology · 2025

DOI: 10.1007/s00246-024-03513-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Cardiology, 2025. Verfasst von Madeline Grossman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Services, Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA, 19104, USA. grossmanm3@chop.edu. Hauptthemen laut MEDLINE: Pyrazines, Acetamides, Antihypertensive Agents, Hypertension, Pulmonary. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This retrospective chart review of patients less than 18 years old with pulmonary arterial hypertension (PAH) receiving selexipag was conducted to describe selexipag dosing practices, impact on concomitant PAH therapies, and the safety and efficacy of selexipag. Twenty-seven patients aged 1-17 years started a median dose of oral selexipag 100 µg twice daily. Therapy was increased by a median of 100 µg twice daily every 6 days to a maximally tolerated median dose of 800 µg twice daily. All 24 patients on another prostacyclin derivative were able to discontinue therapy at their maximum tolerated selexipag dose; other concomitant PAH therapies did not change. Changes in echocardiogram data and 6-MWT results were variable. No patients discontinued selexipag; four patients received decreased doses due to flushing (n = 1), drug interactions (n = 2), or increased frequency of nose bleeds (n = 1).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazinesAcetamidesAntihypertensive AgentsHypertension, PulmonaryPulmonary Arterial HypertensionHumansChildAdolescentMaleFemaleRetrospective StudiesChild, PreschoolInfantTreatment OutcomeDose-Response Relationship, Drug

Stichwörter der Autor:innen

PediatricsProstacyclin derivativeProstacyclin receptor agonistPulmonary hypertensionSelexipag

Substanzen

selexipagPyrazinesAcetamidesAntihypertensive Agents

Autor:innen und Institutionen

  • Department of Pharmacy Services, Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA, 19104, USA. grossmanm3@chop.edu.
  • Division of Pulmonary Hypertension, Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Department of Pharmacy Services, Children's Hospital of Philadelphia, 3401 Civic Center Blvd, Philadelphia, PA, 19104, USA.

Zitieren

APA

Grossman, M., Walker, S., & Ramsey, E. Z. (2025). Selexipag Dosing Strategies for Pediatric Patients with Pulmonary Arterial Hypertension. Pediatric Cardiology. https://doi.org/10.1007/s00246-024-03513-w

Vancouver

Grossman M, Walker S, Ramsey EZ. Selexipag Dosing Strategies for Pediatric Patients with Pulmonary Arterial Hypertension. Pediatric Cardiology. 2025. doi:10.1007/s00246-024-03513-w

BibTeX
@article{Grossman2025,
  author = {Grossman, Madeline and Walker, Stephen and Ramsey, E Zachary},
  title = {Selexipag Dosing Strategies for Pediatric Patients with Pulmonary Arterial Hypertension},
  journal = {Pediatric Cardiology},
  year = {2025},
  doi = {10.1007/s00246-024-03513-w}
}
Kostenlos starten →